文献速递心脏核医学肿瘤 PET/CT

冠状动脉血管运动功能障碍预示乳腺癌患者预后更差

Coronary vasomotor dysfunction portends worse outcomes in patients with breast cancer.
PubMed 文献 · J Nucl Cardiol · 2021-11-24

该回顾性队列研究纳入2006至2017年在布莱根妇女医院接受心脏负荷PET显像的87例乳腺癌患者或幸存者,排除临床显性冠心病、LVEF<45%或心肌灌注异常者,随访至首次主要不良心血管事件(MACE)或全因死亡。中位随访7.6年,最低MFR三分位组较高MFR三分位组MACE累积发生率更高(校正亚分布风险比4.91;95%CI 1.68-14.38;p=0.004)。作者认为冠状动脉血管运动功能障碍与心血管事件相关,MFR可能作为风险分层生物标志物。

要点

  • 乳腺癌患者中,最低MFR三分位组较高MFR三分位组MACE风险更高(校正亚分布HR 4.91;95%CI 1.68-14.38;p=0.004)。
  • 该研究排除临床显性冠心病、LVEF<45%或心肌灌注异常者,提示无血流限制性病变时MFR异常仍与不良事件相关。
  • 作者认为MFR可能作为乳腺癌患者或幸存者的风险分层生物标志物。

核心结论

  • 在乳腺癌患者中,冠状动脉血管运动功能障碍与发生心血管事件相关,MFR可能作为乳腺癌患者或幸存者的风险分层生物标志物。

研究设计与样本

  • 回顾性研究纳入了2006至2017年在布莱根妇女医院连续接受心脏负荷PET显像的乳腺癌患者或乳腺癌幸存者,最终队列87例(中位年龄69.0岁,98.9%为女性,平均MFR 2.05)。

主要发现

  • 中位随访7.6年后,最低MFR三分位组较高MFR三分位组的MACE累积发生率更高(校正亚分布风险比4.91;95%CI 1.68-14.38;p=0.004)。

关键数值与推荐

  • 排除有临床显性冠心病史、LVEF<45%或心肌灌注异常的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Impaired MFR in the absence of flow-limiting CAD is associated with adverse events. Cardiovascular disease is an important cause of morbidity and mortality in patients with breast cancer. We sought to test the utility of MFR to predict outcomes in a cohort of patients with breast cancer. METHODS: We retrospectively studied consecutive patients with breast cancer or breast cancer survivors who underwent cardiac stress PET imaging from 2006 to 2017 at Brigham and Women's Hospital. Patients with a history of clinically overt CAD, LVEF < 45%, or abnormal myocardial perfusion were excluded. Subjects were followed from time of PET to the occurrence of a first major adverse cardiovascular event (MACE) and all-cause death. RESULTS: The final cohort included 87 patients (median age 69.0 years, 98.9% female, mean MFR 2.05). Over a median follow-up of 7.6 years after PET, the lowest MFR tertile was associated with higher cumulative incidence of MACE (adjusted subdistribution hazard ratio 4.91; 95% CI 1.68-14.38; p = 0.004) when compared with the highest MFR tertile. CONCLUSIONS: In patients with breast cancer, coronary vasomotor dysfunction was associated with incident cardiovascular events. MFR may have potential as a risk stratification biomarker among patients with/survivors of breast cancer.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Divakaran S, Caron JP, Zhou W, et al. Coronary vasomotor dysfunction portends worse outcomes in patients with breast cancer. J Nucl Cardiol. 2021. PMID: 34820770. doi:10.1007/s12350-021-02825-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。